Apr 18
BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies: FDA Safety Communication - FDA Investigating Serious Risk of T-cell Malignancy
Biologics
FDA Commissioner Dr. Robert M. Califf discusses nutrition and offers a peek at some new packaging label prototypes.
We know you're busy! The easiest way to keep up with us is to subscribe to our weekly e-newsletter.
You'll get the latest announcements, regulations, and upcoming events delivered to your email inbox every Friday.
Health professionals, consumers and patients can voluntarily report observed or suspected adverse events for human medical products to FDA. Voluntary reporting can help FDA identify unknown risk for approved medical products.
Learn MoreApr 18
Biologics
Apr 26
Medical Devices, Radiation-Emitting Products
Apr 26
Medical Devices
The 50th biosimilar approval milestone also reflects our strategic approach to biosimilars, as outlined in the FDA’s Biosimilars Action Plan.
I recently had the privilege of official travel to the European Union with our global affairs team.
I recently had the privilege of official travel to the U.K. with our global affairs team.
FDA MedWatch Safety Information
You know the moment it happens.
Follow @FDAMedWatch